This report describes and explains the global regenerative medicine market and covers 2016 to 2021, termed the historic period, and 2021 to 2026 termed the forecast period, along with further forecasts for the period 2026-2031. The report evaluates the market across each region and for the major economies within each region.
The global regenerative medicine market reached a value of nearly $7,282.2 million in 2020, having increased at a compound annual growth rate (CAGR) of 54.1% since 2015. The market is expected to grow from $7,282.2 million in 2020 to $22,373.7 million in 2025 at a rate of 25.2%. The market is then expected to grow at a CAGR of 12.7% from 2025 and reach $40,710.1 million in 2030.
Growth in the historic period in the regenerative medicine market resulted from rising prevalence of chronic diseases, emerging markets growth, implementation of the 21st century cures act, rapid growth in aging population, and the improvement in healthcare awareness and expenditure. The market was restrained by high cost of cell and gene therapies, ethical concerns related to the use of embryonic stem cells in research and development, and inadequate reimbursements.
Going forward, rising demand for organ transplantations, growth in healthcare expenditure, technological advancements in regenerative medicines, rising investments in regenerative medicine research, and changes in lifestyles. Factors that could hinder the growth of the market in the future include rising popularity of alternative therapies and natural remedies, low per capita healthcare expenditure, and tissue-engineered products and biomaterials are lagging in adoption.
The regenerative medicine market is segmented by product into cell based, gene based and tissue based. The tissue based segment was the largest segment of the regenerative medicine market segmented by product, accounting for 74.4% of the total in 2020. Going forward, the gene based segment is expected to be the fastest growing segment in the regenerative medicine market segmented by product, at a CAGR of 30.8% during 2020-2025.
The regenerative medicine market is also segmented by end-use into ambulatory surgical centers, hospitals and clinics, and others. The hospitals and clinics segment was the largest segment of the regenerative medicine market segmented by end-use, accounting for 63.8% of the total in 202o. Going forward, hospitals and clinics segment is expected to be the fastest growing segment in the regenerative medicine market segmented by end-use, at a CAGR of 25.3% during 2020-2025.
The regenerative medicine market is also segmented by application into musculoskeletal, oncology, dental, wound care and others. The oncology segment was the largest segment of the regenerative medicine market segmented by application, accounting for 60.0% of the total in 2020. Going forward, musculoskeletal segment is expected to be the fastest growing segment in the regenerative medicine market segmented by application, at a CAGR of 27.4% during 2020-2025.
North America was the largest region in the regenerative medicine market, accounting for 53.3% of the total in 2020. It was followed by the Western Europe, Asia Pacific, and then the other regions. Going forward, the fastest-growing regions in the regenerative medicine market will be Middle East and South America where growth will be at CAGRs of 72.4% and 71.9% respectively during 2020-2025. These will be followed by Eastern Europe and Asia Pacific, where the markets are expected to register CAGRs of 57.8% and 49.7% respectively during 2020-2025.
The disease is highly infectious and contagious in nature, for which the population is not pre-immune. Hence, diagnosis plays a critical role in such diseases. The number of people infected with the COVID-19 virus has been increasing significantly which calls for the need to shorten the time taken for diagnosis and treatment, better and accurate detection speeds, and the development of innovative molecular diagnostic techniques. The availability of efficient and accurate laboratory diagnosis is critical for the effective prevention and control of the pandemic. Early detection, diagnosis, isolation, and treatment is the most effective way to prevent and control COVID 19. The COVID-19 impacted the global regenerative medicine market in the initial phase pandemic. Elective surgeries were cancelled or postponed to reserve the available limited capacities and resources such as hospital beds and healthcare professionals toward COVID-19 patient care. Moreover, to control the rising number of positive COVID-19 cases, several countries implemented lockdowns and curfews. Furthermore, patients were unable to visit hospitals, clinics, or OPDs due to the lockdowns. The regeneration industries are projected to be hindered by the temporary denial of wound care services, cancer care surgeries/therapies, and other healthcare services.
The global regenerative medicine market is fragmented, with a large number of players. The top ten competitors in the market made up to xx% of the total market in 2020. Companies in the market are expanding their business by adopting various strategies, such as mergers and acquisitions, while others are focusing on expanding its product portfolio by launching new products with advanced technology to retain their market share. Major players in the market are Smith & Nephew plc, Integra LifeSciences, Stryker Corporation, MiMedx Group, Inc., Zimmer Biomet Holdings Inc., B. Braun Melsungen AG, AbbVie, CONMED Corporation, Arthrex Inc., Baxter International Inc. and other players.
The top opportunities in the regenerative medicine market segmented by product will arise in tissue based segment, which will gain $11,532.7millions of global annual sales by 2025. The top opportunities in the regenerative medicine market segmented by end-use will arise in hospitals & clinics segment, which will gain $10,482.5millions of global annual sales by 2025. The top opportunities in the regenerative medicine market segmented by application will arise in oncology segment, which will gain $9,624.7 million of global annual sales by 2025. The regenerative medicine market size will gain the most in the USA at $5,031.7 million.
Market-trend-based strategies for the regenerative medicine include growing use of mesenchymal stem cell technology, increasing research and development on use of novel gene therapy techniques, advancements in technology transfer and clinical translation, rising strategic collaborations, partnerships and agreements, growth and advent of new companies, injectable hydrogel role in cartilage repair as a regenerative medicine, and global research initiatives and funding.
Player-adopted strategies in the regenerative medicine market includes strengthening its business by acquiring companies with same business, focus on research and development of new products and for the same is getting into partnerships and collaborations, and focusing on expanding its product portfolio by launching new products with advanced technology.
To take advantage of the opportunities, the publisher reccomends the regenerative medicine companies to focus on Mesenchymal stem cell technology, focus on strategic collaborations, partnerships and agreements, expand in emerging markets, provide competitively priced offerings in low-income countries, offer value-based pricing, participate in trade shows and events, focus on patient referral systems, target the elderly population and target hospitals and pharmacies to spread awareness.
The global regenerative medicine market reached a value of nearly $7,282.2 million in 2020, having increased at a compound annual growth rate (CAGR) of 54.1% since 2015. The market is expected to grow from $7,282.2 million in 2020 to $22,373.7 million in 2025 at a rate of 25.2%. The market is then expected to grow at a CAGR of 12.7% from 2025 and reach $40,710.1 million in 2030.
Growth in the historic period in the regenerative medicine market resulted from rising prevalence of chronic diseases, emerging markets growth, implementation of the 21st century cures act, rapid growth in aging population, and the improvement in healthcare awareness and expenditure. The market was restrained by high cost of cell and gene therapies, ethical concerns related to the use of embryonic stem cells in research and development, and inadequate reimbursements.
Going forward, rising demand for organ transplantations, growth in healthcare expenditure, technological advancements in regenerative medicines, rising investments in regenerative medicine research, and changes in lifestyles. Factors that could hinder the growth of the market in the future include rising popularity of alternative therapies and natural remedies, low per capita healthcare expenditure, and tissue-engineered products and biomaterials are lagging in adoption.
The regenerative medicine market is segmented by product into cell based, gene based and tissue based. The tissue based segment was the largest segment of the regenerative medicine market segmented by product, accounting for 74.4% of the total in 2020. Going forward, the gene based segment is expected to be the fastest growing segment in the regenerative medicine market segmented by product, at a CAGR of 30.8% during 2020-2025.
The regenerative medicine market is also segmented by end-use into ambulatory surgical centers, hospitals and clinics, and others. The hospitals and clinics segment was the largest segment of the regenerative medicine market segmented by end-use, accounting for 63.8% of the total in 202o. Going forward, hospitals and clinics segment is expected to be the fastest growing segment in the regenerative medicine market segmented by end-use, at a CAGR of 25.3% during 2020-2025.
The regenerative medicine market is also segmented by application into musculoskeletal, oncology, dental, wound care and others. The oncology segment was the largest segment of the regenerative medicine market segmented by application, accounting for 60.0% of the total in 2020. Going forward, musculoskeletal segment is expected to be the fastest growing segment in the regenerative medicine market segmented by application, at a CAGR of 27.4% during 2020-2025.
North America was the largest region in the regenerative medicine market, accounting for 53.3% of the total in 2020. It was followed by the Western Europe, Asia Pacific, and then the other regions. Going forward, the fastest-growing regions in the regenerative medicine market will be Middle East and South America where growth will be at CAGRs of 72.4% and 71.9% respectively during 2020-2025. These will be followed by Eastern Europe and Asia Pacific, where the markets are expected to register CAGRs of 57.8% and 49.7% respectively during 2020-2025.
The disease is highly infectious and contagious in nature, for which the population is not pre-immune. Hence, diagnosis plays a critical role in such diseases. The number of people infected with the COVID-19 virus has been increasing significantly which calls for the need to shorten the time taken for diagnosis and treatment, better and accurate detection speeds, and the development of innovative molecular diagnostic techniques. The availability of efficient and accurate laboratory diagnosis is critical for the effective prevention and control of the pandemic. Early detection, diagnosis, isolation, and treatment is the most effective way to prevent and control COVID 19. The COVID-19 impacted the global regenerative medicine market in the initial phase pandemic. Elective surgeries were cancelled or postponed to reserve the available limited capacities and resources such as hospital beds and healthcare professionals toward COVID-19 patient care. Moreover, to control the rising number of positive COVID-19 cases, several countries implemented lockdowns and curfews. Furthermore, patients were unable to visit hospitals, clinics, or OPDs due to the lockdowns. The regeneration industries are projected to be hindered by the temporary denial of wound care services, cancer care surgeries/therapies, and other healthcare services.
The global regenerative medicine market is fragmented, with a large number of players. The top ten competitors in the market made up to xx% of the total market in 2020. Companies in the market are expanding their business by adopting various strategies, such as mergers and acquisitions, while others are focusing on expanding its product portfolio by launching new products with advanced technology to retain their market share. Major players in the market are Smith & Nephew plc, Integra LifeSciences, Stryker Corporation, MiMedx Group, Inc., Zimmer Biomet Holdings Inc., B. Braun Melsungen AG, AbbVie, CONMED Corporation, Arthrex Inc., Baxter International Inc. and other players.
The top opportunities in the regenerative medicine market segmented by product will arise in tissue based segment, which will gain $11,532.7millions of global annual sales by 2025. The top opportunities in the regenerative medicine market segmented by end-use will arise in hospitals & clinics segment, which will gain $10,482.5millions of global annual sales by 2025. The top opportunities in the regenerative medicine market segmented by application will arise in oncology segment, which will gain $9,624.7 million of global annual sales by 2025. The regenerative medicine market size will gain the most in the USA at $5,031.7 million.
Market-trend-based strategies for the regenerative medicine include growing use of mesenchymal stem cell technology, increasing research and development on use of novel gene therapy techniques, advancements in technology transfer and clinical translation, rising strategic collaborations, partnerships and agreements, growth and advent of new companies, injectable hydrogel role in cartilage repair as a regenerative medicine, and global research initiatives and funding.
Player-adopted strategies in the regenerative medicine market includes strengthening its business by acquiring companies with same business, focus on research and development of new products and for the same is getting into partnerships and collaborations, and focusing on expanding its product portfolio by launching new products with advanced technology.
To take advantage of the opportunities, the publisher reccomends the regenerative medicine companies to focus on Mesenchymal stem cell technology, focus on strategic collaborations, partnerships and agreements, expand in emerging markets, provide competitively priced offerings in low-income countries, offer value-based pricing, participate in trade shows and events, focus on patient referral systems, target the elderly population and target hospitals and pharmacies to spread awareness.
Table of Contents
1. Regenerative Medicine Market Executive Summary2. Table of Contents3. List of Figures4. List of Tables5. Report Structure
6. Introduction
7. Regenerative Medicine Market Characteristics
8. Regenerative Medicine Market Trends And Strategies
9. Impact Of COVID-19 On Regenerative Medicine
10. Global Regenerative Medicine Market Size And Growth
11. Global Regenerative Medicine Market Segmentation
12. Regenerative Medicine Market, Regional And Country Analysis
13. Asia-Pacific Regenerative Medicine Market
14. Western Europe Regenerative Medicine Market
15. Eastern Europe Regenerative Medicine Market
16. North America Regenerative Medicine Market
17. South America Regenerative Medicine Market
18. Middle East Regenerative Medicine Market
19. Africa Regenerative Medicine Market
20. Regenerative Medicine Global Market Competitive Landscape
21. Key Mergers And Acquisitions In The Regenerative Medicine Market
22. Regenerative Medicine Market Opportunities And Strategies
23. Regenerative Medicine Market, Conclusions And Recommendations
24. Appendix
Executive Summary
Regenerative Medicine Global Market Opportunities And Strategies To 2031 provides the strategists; marketers and senior management with the critical information they need to assess the global regenerative medicine market as it emerges from the COVID 19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors. .
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description:
Where is the largest and fastest growing market for regenerative medicine? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The regenerative medicine market global report answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider regenerative medicine market; and compares it with other markets.
The report covers the following chapters
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report.
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction - The introduction section of the report gives a brief introduction about segmentation by geography, segmentation by product, segmentation by application and segmentation by end-use.
- Market Characteristics - The market characteristics section of the report defines and explains the regenerative medicine market. This chapter also defines and describes goods and related services covered in the report.
- Trends And Strategies - This chapter describes the major trends shaping the global regenerative medicine market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- Impact of COVID-19 - This section describes the impact of COVID-19 on the regenerative medicine market.
- Global Market Size And Growth - This section contains the global historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional Analysis - This section contains the historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values and growth and market share comparison by region.
- Segmentation - This section contains the market values (2015-2030) and analysis for different segments.
- Regional Market Size and Growth - This section contains the region’s market size (2020), historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa, and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
- Competitive Landscape - This section covers details on the competitive landscape of the global regenerative medicine market, estimated market shares, and company profiles for the leading players.
- Key Mergers And Acquisitions - This chapter gives information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities And Strategies - This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for regenerative medicine providers in terms of product offerings, geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS (North American Industry Classification System) codes covered, abbreviations, and currencies codes used in this report.
Markets Covered:
- By Product: Cell Based; Gene Based; Tissue Based
- By End-Use: Ambulatory Surgical Centers; Hospitals And Clinics; Others
- By Application: Musculoskeletal; Oncology; Dental; Wound Care; Others
Companies Mentioned:
Smith & Nephew plc; Integra LifeSciences; Stryker Corporation; MiMedx Group, Inc.; Zimmer Biomet Holdings Inc.
Countries:
China, Japan, India, Australia, USA, Brazil, UK, Germany, France, Spain, Italy, Russia, South Korea, Singapore, Thailand, Indonesia, Vietnam, Philippines, Malaysia, New Zealand, Hong Kong, Belgium, Sweden, Austria, Denmark, Netherlands, Norway, Finland, Portugal, Switzerland, Ireland, Poland, Czech Republic, Romania, Canada, Mexico, Argentina, Peru, Venezuela, Colombia, Chile, Saudi Arabia, Turkey, UAE, Israel, South Africa, Egypt, Nigeria
Regions:
Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series:
Five years historic and ten years forecast.
Data:
Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; regenerative medicine indicators comparison.
Data segmentations:
country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing:
Data and analysis throughout the report is sourced using end notes.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Smith & Nephew plc
- Integra LifeSciences
- Stryker Corporation
- MiMedx Group, Inc.
- Zimmer Biomet Holdings Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 416 |
| Published | July 2022 |
| Forecast Period | 2021 - 2030 |
| Estimated Market Value ( USD | $ 7282.2 Million |
| Forecasted Market Value ( USD | $ 40710.1 Million |
| Compound Annual Growth Rate | 18.8% |
| Regions Covered | Global |
